CAB-CTLA-4 (BA3071)
Advanced Solid Tumors
Phase 1/2Terminated (Nov 2022)
Key Facts
About BioAtla
BioAtla is pioneering a novel class of therapeutics called Conditionally Active Biologics (CABs), designed to be active only in the specific physiological conditions of diseased tissue, such as the acidic, hypoxic tumor microenvironment. This approach aims to unlock previously undruggable targets and improve the safety and efficacy of cancer therapies. The company has built a robust intellectual property portfolio with over 700 patents and applications and is led by a seasoned team with decades of biotech experience. Its strategy focuses on advancing its internal CAB pipeline while exploring potential partnerships for its platform technology.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |